Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.17
-0.06 (-0.83%)
At close: Apr 28, 2026, 4:00 PM EDT
7.32
+0.15 (2.09%)
After-hours: Apr 28, 2026, 6:50 PM EDT
Unicycive Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Unicycive Therapeutics stock have an average target of 25.67, with a low estimate of 15 and a high estimate of 40. The average target predicts an increase of 258.02% from the current stock price of 7.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Unicycive Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +109.21% | Apr 6, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $46 → $40 | Strong Buy | Maintains | $46 → $40 | +457.88% | Apr 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $22 | Strong Buy | Maintains | $9 → $22 | +206.83% | Oct 29, 2025 |
| Benchmark | Benchmark | Buy Maintains $3 → $21 | Buy | Maintains | $3 → $21 | +192.89% | Sep 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $90 | Strong Buy | Initiates | $90 | +1,155.23% | May 27, 2025 |
Financial Forecast
Revenue This Year
70.35M
Revenue Next Year
480.39M
from 70.35M
Increased by 582.86%
EPS This Year
-1.35
from -1.67
EPS Next Year
15.03
from -1.35
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 241.2M | 1.2B | ||||||
| Avg | 70.4M | 480.4M | ||||||
| Low | 7.3M | 91.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,598.6% | ||||||
| Avg | - | 582.9% | ||||||
| Low | - | 29.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.95 | 30.60 | ||||||
| Avg | -1.35 | 15.03 | ||||||
| Low | -1.72 | 6.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.